SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Innoviva, Inc. (INVA) News

Follow Innoviva, Inc. (INVA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol INVA Asset equity Sector Markets 90 days 9 Last 18.43 Updated Nov 04, 2026, 09:34 PM UTC Open live news feed Open INVA chart & news
M Innoviva U.S. Net Product Sales Rose 45% to $43.3M in Q3 Innoviva said it remains on track to achieve 2026 guidance of at least $150 million in U.S. net product sales. EQUITY | Nov 04, 2026, 09:34 PM UTC M Innoviva Reports Q3 Pretax Loss Innoviva reported a Q3 net loss. EQUITY | Nov 04, 2026, 09:12 PM UTC M Innoviva Reports Third-Quarter 2026 Financial Results Innoviva reported its third-quarter 2026 financial results. EQUITY | Nov 04, 2026, 09:06 PM UTC M Innoviva Q3'26 Earnings Preview: Revenue Estimate Innoviva is scheduled to report Q3'26 results on November 11. Revenue and EPS estimates were provided; the release time is not specified. EQUITY | Nov 04, 2026, 12:00 PM UTC L Innoviva Coverage Assumed by Oppenheimer at Outperform Ratings actions from Benzinga: GMT) Innoviva Price Target Announced at $35.00/Share by OppenheimerRatings actions from Benzinga NEWS | Sep 23, 2026, 12:24 PM UTC L INVA: Specialty therapeutics and innovative drug delivery drive growth, with resilient royalty streams funding expansion Specialty therapeutics revenue exceeded $200 million, driven by XACDURO and GIAPREZA, with strong U.S. and ex-U.S. growth. Nortiva's LYNX platform targets once-monthly oral contraceptives, supported by the Gates Foundati EQUITY | Sep 10, 2026, 01:40 PM UTC L INVA: Specialty therapeutics and innovative drug delivery drive growth, backed by stable royalties Specialty therapeutics revenue exceeded $200 million, driven by strong growth in XACDURO and GIAPREZA, with global expansion through partnerships. Nortiva's LYNX platform targets once-monthly dosing, starting with a cont EQUITY | Sep 10, 2026, 01:02 PM UTC L INVA - Innoviva to Participate in Upcoming Investor Conferences INVA - Innoviva to Participate in Upcoming Investor Conferences EQUITY | Sep 02, 2026, 12:08 PM UTC L Innoviva to participate in upcoming investor conferences Innoviva says it will participate in upcoming investor conferences. The company describes its diversified biopharmaceutical focus, including a royalties portfolio and critical care and infectious disease platform. EQUITY | Sep 02, 2026, 12:00 PM UTC L INVA Therapies Named Finalists for Prix Galien USA Award Innoviva Specialty Therapeutics' XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA Best Pharmaceutical Product Award EQUITY | Aug 11, 2026, 08:12 PM UTC L Innoviva Therapies Named Finalists Innoviva's XACDURO, ZEVTERA, and NUZOLVENCE are finalists for the Prix Galien USA award EQUITY | Aug 11, 2026, 08:05 PM UTC L INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress INVA - Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress EARNINGS | Aug 05, 2026, 08:17 PM UTC